Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
- Indications Bone cancer; Leukaemia; Lymphoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 20 Apr 2020 Results (N=24), subgroup analysis of an expansion cohort assessing tolerability and drug activity patients with refractory or recurrent solid tumors, published in the European Journal of Cancer
- 27 Aug 2019 Results assessing population pharmacokinetic modeling by using data from two studies (RELHEM and ANGIO1) published in the Clinical Cancer Research.
- 07 Jun 2016 Results from an expansion part of this trial (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology